SG10201501784YA - Methods for enhancing anti-tumor antibody therapy - Google Patents

Methods for enhancing anti-tumor antibody therapy

Info

Publication number
SG10201501784YA
SG10201501784YA SG10201501784YA SG10201501784YA SG10201501784YA SG 10201501784Y A SG10201501784Y A SG 10201501784YA SG 10201501784Y A SG10201501784Y A SG 10201501784YA SG 10201501784Y A SG10201501784Y A SG 10201501784YA SG 10201501784Y A SG10201501784Y A SG 10201501784YA
Authority
SG
Singapore
Prior art keywords
methods
antibody therapy
tumor antibody
enhancing anti
enhancing
Prior art date
Application number
SG10201501784YA
Other languages
English (en)
Inventor
Holbrook Kohrt
Roch Houot
Ronald Levy
Arash Ash Alizadeh
Matthew J Goldstein
James Torchia
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG10201501784YA publication Critical patent/SG10201501784YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201501784YA 2009-12-07 2010-12-07 Methods for enhancing anti-tumor antibody therapy SG10201501784YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26733709P 2009-12-07 2009-12-07
US28706709P 2009-12-16 2009-12-16
US35830310P 2010-06-24 2010-06-24

Publications (1)

Publication Number Publication Date
SG10201501784YA true SG10201501784YA (en) 2015-05-28

Family

ID=44145876

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201501784YA SG10201501784YA (en) 2009-12-07 2010-12-07 Methods for enhancing anti-tumor antibody therapy
SG2012041505A SG181533A1 (en) 2009-12-07 2010-12-07 Methods for enhancing anti-tumor antibody therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012041505A SG181533A1 (en) 2009-12-07 2010-12-07 Methods for enhancing anti-tumor antibody therapy

Country Status (11)

Country Link
US (3) US9005619B2 (fr)
EP (1) EP2509627B1 (fr)
JP (1) JP5950824B2 (fr)
KR (1) KR101853702B1 (fr)
CN (1) CN102753195A (fr)
AU (3) AU2010328347B2 (fr)
BR (1) BR112012013736A2 (fr)
CA (1) CA2781311C (fr)
MX (1) MX346912B (fr)
SG (2) SG10201501784YA (fr)
WO (1) WO2011071871A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
WO2011071871A1 (fr) 2009-12-07 2011-06-16 The Board Of Trustees Of The Leland Stanford Junior University Méthodes d'amplification d'un traitement à base d'anticorps anticancéreux
EA029793B1 (ru) 2010-08-23 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела к ох40 и способы их применения
SG188313A1 (en) 2010-09-09 2013-04-30 Pfizer 4-1bb binding molecules
CA3019531A1 (fr) * 2011-04-19 2012-10-26 Pfizer Inc. Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
CN105579058A (zh) * 2013-07-15 2016-05-11 小利兰·斯坦福大学托管委员会 Cd38激动剂的医学用途
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
TW202132337A (zh) 2014-05-28 2021-09-01 美商艾吉納斯公司 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
WO2015188047A1 (fr) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
WO2016054638A1 (fr) * 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
HUE049938T2 (hu) 2015-03-23 2020-11-30 Jounce Therapeutics Inc Icos elleni antitestek
WO2016167809A1 (fr) * 2015-04-17 2016-10-20 The Board Of Trustees Of The Leland Stanford Junior University Traitement par t-dm1 amélioré
EP3091031A1 (fr) * 2015-05-04 2016-11-09 Affimed GmbH Combinaison d'un anticorps bispécifique avec une molécule modulatrice immunitaire pour le traitement d'une tumeur
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
PL3303396T3 (pl) 2015-05-29 2023-03-06 Bristol-Myers Squibb Company Przeciwciała przeciwko ox40 i ich zastosowanie
JP2018524404A (ja) * 2015-07-07 2018-08-30 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） Ｎｋ細胞殺傷活性を増強する方法および医薬組成物
MX2018000948A (es) 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
WO2017040374A1 (fr) * 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Compositions et procédés d'amélioration de la réponse antitumorale à l'aide des neutrophiles hybrides
CA2992863A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps bispecifiques specifiques d'un recepteur de co-stimulation du tnf
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP2019519536A (ja) 2016-07-01 2019-07-11 ファイブ プライム セラピューティクス， インコーポレイテッド Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
GB201613167D0 (en) * 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CA3032897A1 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CA3041340A1 (fr) 2016-11-09 2018-05-17 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation
KR102585848B1 (ko) 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
SG10201913144TA (en) 2017-07-11 2020-03-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11698367B2 (en) 2017-09-15 2023-07-11 Beckman Coulter, Inc. Flow based assays for therapeutics
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (fr) 2017-11-20 2019-05-23 Compass Therapeutics Llc Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
KR20200131282A (ko) * 2018-03-13 2020-11-23 에프. 호프만-라 로슈 아게 표적화된 4-1bb(cd137) 작용제에 의한 조합 치료
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
US20200046737A1 (en) * 2018-08-09 2020-02-13 Notable Labs, Inc. Methods for treating cancer, and compositions therefor
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
BR112021013571A2 (pt) * 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
EP3958908A1 (fr) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Conjugués anticorps-médicaments d'amatoxine et leurs utilisations
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
JP2023508624A (ja) * 2019-10-18 2023-03-03 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル Ｎｋ細胞上で受容体を結合させるための複数のリガンドとコンジュゲートしたナノ粒子を使用したがん処置のための方法及び組成物
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
CN113491768A (zh) * 2020-04-01 2021-10-12 深圳市罗湖区人民医院 Cd137抗体在制备促进nk细胞表达cd16分子的药物中的应用
WO2021202917A1 (fr) * 2020-04-01 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Approche multiparamétrique non invasive pour l'identification précoce d'un bénéfice thérapeutique à partir de l'inhibition du point de contrôle immunitaire pour le cancer du poumon
EP4172323A1 (fr) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (fr) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Systèmes récepteurs antigéniques chimériques ayant une spécificité de récepteur adaptable
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006029275A2 (fr) 2004-09-08 2006-03-16 Genentech, Inc. Methodes d'utilisation de ligands de recepteurs de mort, ainsi que d'anticorps cd20
WO2006116246A2 (fr) 2005-04-25 2006-11-02 Medarex, Inc. Methode de traitement des lymphomes cd30 positif
EP2495257A3 (fr) * 2005-08-19 2012-10-17 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
WO2011071871A1 (fr) * 2009-12-07 2011-06-16 The Board Of Trustees Of The Leland Stanford Junior University Méthodes d'amplification d'un traitement à base d'anticorps anticancéreux
WO2011146382A1 (fr) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Régimes posologiques immunothérapeutiques améliorés et combinaisons de ceux-ci
WO2012027536A1 (fr) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives
CN103476407A (zh) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2887027C (fr) 2012-10-02 2021-11-16 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et d'anticorps anti-pd-1 pour le traitement du cancer
WO2014066532A1 (fr) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer

Also Published As

Publication number Publication date
CA2781311A1 (fr) 2011-06-16
AU2016201190A1 (en) 2016-03-17
AU2010328347B2 (en) 2015-12-17
EP2509627A4 (fr) 2013-12-25
BR112012013736A2 (pt) 2018-08-14
US9005619B2 (en) 2015-04-14
CA2781311C (fr) 2019-03-12
WO2011071871A1 (fr) 2011-06-16
US9758589B2 (en) 2017-09-12
US10633450B2 (en) 2020-04-28
KR20120102714A (ko) 2012-09-18
JP5950824B2 (ja) 2016-07-13
EP2509627A1 (fr) 2012-10-17
CN102753195A (zh) 2012-10-24
EP2509627B1 (fr) 2017-01-25
KR101853702B1 (ko) 2018-05-03
US20160083474A1 (en) 2016-03-24
AU2010328347A1 (en) 2012-06-21
JP2013512958A (ja) 2013-04-18
SG181533A1 (en) 2012-07-30
US20120321646A1 (en) 2012-12-20
US20180208670A1 (en) 2018-07-26
MX346912B (es) 2017-04-05
AU2017268492A1 (en) 2017-12-14
MX2012006420A (es) 2012-12-05

Similar Documents

Publication Publication Date Title
SG10201501784YA (en) Methods for enhancing anti-tumor antibody therapy
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
EP2785743A4 (fr) Anticorps recombinants anti-ceacam1 pour la thérapie de cancer
ZA201306944B (en) Individualized vaccines for cancer
IL229254A0 (en) Therapeutic antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2427496A4 (fr) Anticorps anti-vegf-d
EP2635286A4 (fr) Méthodes de traitement du cancer
PT2493565T (pt) Método de fornecimento de radioterapia
GB0920324D0 (en) Antibodies
GB0815788D0 (en) Therapeutic antibodies
EP2499256A4 (fr) Anticorps anti-c-mpl
EP2324059A4 (fr) Anticorps thérapeutiques anti-pamp
EP2281575A4 (fr) Anticorps destinés au traitement du cancer
PL2714071T3 (pl) Zindywidualizowane szczepionki przeciwrakowe
EP2424892A4 (fr) Anticorps anti-dc-stamp
GB0902916D0 (en) Antibody therapy
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy
ZA201208905B (en) Cancer therapy method
ZA201308992B (en) Therapeutic antibodies
GB0908945D0 (en) Antibodies